369 related articles for article (PubMed ID: 31416718)
1. Management of the aging beta-thalassemia transfusion-dependent population - The Italian experience.
Pinto VM; Poggi M; Russo R; Giusti A; Forni GL
Blood Rev; 2019 Nov; 38():100594. PubMed ID: 31416718
[TBL] [Abstract][Full Text] [Related]
2. Thalassemia.
Aydinok Y
Hematology; 2012 Apr; 17 Suppl 1():S28-31. PubMed ID: 22507773
[TBL] [Abstract][Full Text] [Related]
3. Endocrinopathies, metabolic disorders, and iron overload in major and intermedia thalassemia: serum ferritin as diagnostic and predictive marker associated with liver and cardiac T2* MRI assessment.
Chirico V; Rigoli L; Lacquaniti A; Salpietro V; Piraino B; Amorini M; Salpietro C; Arrigo T
Eur J Haematol; 2015 May; 94(5):404-12. PubMed ID: 25200112
[TBL] [Abstract][Full Text] [Related]
4. Thalassemia Intermedia: Chelator or Not?
Lee YC; Yen CT; Lee YL; Chen RJ
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077584
[TBL] [Abstract][Full Text] [Related]
5. Iron overload and iron-chelating therapy in hemoglobin E-beta thalassemia.
Olivieri NF; De Silva S; Premawardena A; Sharma S; Viens AM; Taylor CM; Brittenham GM; Weatherall DJ
J Pediatr Hematol Oncol; 2000; 22(6):593-7. PubMed ID: 11132236
[TBL] [Abstract][Full Text] [Related]
6. Thalassemia Major: Transplantation or Transfusion and Chelation.
Mohamed SY
Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):290-298. PubMed ID: 28651066
[TBL] [Abstract][Full Text] [Related]
7. Iron overload in β-thalassemia intermedia: an emerging concern.
Musallam KM; Cappellini MD; Taher AT
Curr Opin Hematol; 2013 May; 20(3):187-92. PubMed ID: 23426199
[TBL] [Abstract][Full Text] [Related]
8. Systematic Literature Review of the Burden of Disease and Treatment for Transfusion-dependent β-Thalassemia.
Betts M; Flight PA; Paramore LC; Tian L; Milenković D; Sheth S
Clin Ther; 2020 Feb; 42(2):322-337.e2. PubMed ID: 31882227
[TBL] [Abstract][Full Text] [Related]
9. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications.
Farmaki K; Tzoumari I; Pappa C
Blood Cells Mol Dis; 2011 Jun; 47(1):33-40. PubMed ID: 21531154
[TBL] [Abstract][Full Text] [Related]
10. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.
Marsella M; Borgna-Pignatti C
Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709
[TBL] [Abstract][Full Text] [Related]
11. Morbidities and mortality in transfusion-dependent Beta-thalassemia patients (single-center experience).
Mokhtar GM; Gadallah M; El Sherif NH; Ali HT
Pediatr Hematol Oncol; 2013 Mar; 30(2):93-103. PubMed ID: 23301991
[TBL] [Abstract][Full Text] [Related]
12. Retinal abnormalities in β-thalassemia major.
Bhoiwala DL; Dunaief JL
Surv Ophthalmol; 2016; 61(1):33-50. PubMed ID: 26325202
[TBL] [Abstract][Full Text] [Related]
13. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
[TBL] [Abstract][Full Text] [Related]
14. [Current management of thalassemia intermedia].
Thuret I
Transfus Clin Biol; 2014 Nov; 21(4-5):143-9. PubMed ID: 25282488
[TBL] [Abstract][Full Text] [Related]
15. Iron Chelation Therapy as a Modality of Management.
Aydinok Y
Hematol Oncol Clin North Am; 2018 Apr; 32(2):261-275. PubMed ID: 29458731
[TBL] [Abstract][Full Text] [Related]
16. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
Saliba AN; El Rassi F; Taher AT
Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
[TBL] [Abstract][Full Text] [Related]
17. Beta-thalassemia.
Rund D; Rachmilewitz E
N Engl J Med; 2005 Sep; 353(11):1135-46. PubMed ID: 16162884
[No Abstract] [Full Text] [Related]
18. Challenges in chronic transfusion for patients with thalassemia.
Lal A
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):160-166. PubMed ID: 33275743
[TBL] [Abstract][Full Text] [Related]
19. Management of transfusion-dependent β-thalassemia (TDT): Expert insights and practical overview from the Middle East.
El-Beshlawy A; Dewedar H; Hindawi S; Alkindi S; Tantawy AA; Yassin MA; Taher AT
Blood Rev; 2024 Jan; 63():101138. PubMed ID: 37867006
[TBL] [Abstract][Full Text] [Related]
20. Thalassemia.
Cohen AR; Galanello R; Pennell DJ; Cunningham MJ; Vichinsky E
Hematology Am Soc Hematol Educ Program; 2004; ():14-34. PubMed ID: 15561674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
